ML
Therapeutic Areas
Iterion Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Tegavivint | Advanced Hepatocellular Carcinoma (HCC) with Wnt/β-catenin mutations | Phase 1b/2a |
Leadership Team at Iterion Therapeutics
RW
Ryan Walker
Media Contact (RJ Walker Co.)
LW
Laurence Watts
Investor Relations Contact (New Street IR)